These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17904355)

  • 21. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
    Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
    Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant kinase signaling: lessons from head and neck cancer.
    Nelson EG; Grandis JR
    Future Oncol; 2007 Jun; 3(3):353-61. PubMed ID: 17547530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular-targeted therapies in head and neck cancer.
    Rao SD; Fury MG; Pfister DG
    Semin Radiat Oncol; 2012 Jul; 22(3):207-13. PubMed ID: 22687945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapy: A novel approach in head and neck cancer.
    Christy AW; Bojan A
    Indian J Dent Res; 2013; 24(2):261-6. PubMed ID: 23965459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.
    Blaszczak W; Barczak W; Wegner A; Golusinski W; Suchorska WM
    Med Oncol; 2017 Apr; 34(4):60. PubMed ID: 28315228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel targeted therapies in head and neck cancer.
    Ferreira MB; Lima JP; Cohen EE
    Expert Opin Investig Drugs; 2012 Mar; 21(3):281-95. PubMed ID: 22239178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mouse models for human head and neck squamous cell carcinomas.
    Lu SL; Herrington H; Wang XJ
    Head Neck; 2006 Oct; 28(10):945-54. PubMed ID: 16721744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Sacco AG; Cohen EE
    J Clin Oncol; 2015 Oct; 33(29):3305-13. PubMed ID: 26351341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecularly targeted therapies in head and neck cancers.
    Sawicki M; Szudy A; Szczyrek M; Krawczyk P; Klatka J
    Otolaryngol Pol; 2012; 66(5):307-12. PubMed ID: 23036118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR-targeting monoclonal antibodies in head and neck cancer.
    Astsaturov I; Cohen RB; Harari P
    Curr Cancer Drug Targets; 2007 Nov; 7(7):650-65. PubMed ID: 18045070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular therapy in head and neck oncology.
    Bernier J; Bentzen SM; Vermorken JB
    Nat Rev Clin Oncol; 2009 May; 6(5):266-77. PubMed ID: 19390553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New approaches in metastatic melanoma: biological and molecular targeted therapies.
    Lejeune FJ; Rimoldi D; Speiser D
    Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted therapy in head and neck cancer.
    Kundu SK; Nestor M
    Tumour Biol; 2012 Jun; 33(3):707-21. PubMed ID: 22373581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.
    Moreira J; Tobias A; O'Brien MP; Agulnik M
    Drugs; 2017 May; 77(8):843-857. PubMed ID: 28382569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autophagic action of new targeting agents in head and neck oncology.
    Rikiishi H
    Cancer Biol Ther; 2012 Sep; 13(11):978-91. PubMed ID: 22825332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review.
    Muratori L; La Salvia A; Sperone P; Di Maio M
    Crit Rev Oncol Hematol; 2019 Jul; 139():41-52. PubMed ID: 31112881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review.
    Sanwick AM; Chaple IF
    Front Oncol; 2024; 14():1445191. PubMed ID: 39239273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promising new targeted agents in head and neck cancer.
    Siu LL
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S59-60. PubMed ID: 17848297
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors.
    Sacco AG; Worden FP
    Onco Targets Ther; 2016; 9():1927-43. PubMed ID: 27110122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapeutic targets in squamous cell carcinoma of the head and neck.
    Cohen EE
    Semin Oncol; 2004 Dec; 31(6):755-68. PubMed ID: 15599853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.